TrialAnnals of oncology : official journal of the European Society for Medical Oncology2012

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

L K Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.